Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B OR C: Case series and literature review

Pharmacotherapy

Volumn 25, Issue 8, 2005, Pages 1068-1072

  Robertson, Sarah M ^a   Scarsi, Kimberly K ^b   Postelnick, Michael J ^b   Lynch, Patrick ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Coinfection; Hepatitis B; Hepatitis C; HIV; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

ATAZANAVIR; DRUG METABOLITE; EFAVIRENZ; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL ARTICLE; COMORBIDITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MONITORING; DRUG TRANSFORMATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 23244464566     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.8.1068     Document Type: Review

References (20)

1. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002;16(suppl):S5-37.
2. US Department of Health and Human Services. 2004 guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Rockville, MD: HIV/AIDS Treatment Information Service. Available from http://aidsinfo.nih. gov/guidelines. Accessed May 15, 2004.
3. Bruno R, Sacchi P, Pouti M, Soriano V, Gilice G. HCV chronic hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 2002;97:1598-606.
4. Dodig M, Tavill AS. Hepatitis C and human immunodeficiency virus coinfections. J Clin Gastroenterol 2001;33:367-74.
5. Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease [letter]. AIDS 1999;13:870.
6. Fisk W, Benedek I, Brennan J, et al. Pharmacokinetics of efavirenz in subjects with chronic liver disease. Presented at the 6th conference on retroviruses and opportunistic infections, Chicago, IL, January 31-February 4, 1999.
7. Nunez M, Gonzalez-Requena D, Gonzalez-Lahoz J, Soriano V. Interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. AIDS Res Hum Retroviruses 2003;19:187-8.
8. Lavrut T, Héripret L, Durant J, et al. Pharmacokinetics of nevirapine in HIV-HCV-coinfected patients. Presented at the 5th international workshop on clinical pharmacology of HIV therapy, Rome, Italy, April 1-3, 2004.
9. Abbott Laboratories. Kaletra (lopinavir-ritonavir) package insert. North Chicago, IL; 2004.
10. Bristol-Myers Squibb. Sustiva (efavirenz) package insert. Princeton, NJ; 2004.
11. Agouron Pharmaceuticals, Inc. Viracept (nelfinavir) package insert. LaJolla, CA; 2004.
12. Boehringer Ingelheim Pharmaceuticals, Inc. Viramune (nevirapine) package insert. Ridgefield, CT; 2004.
13. Bristol-Myers Squibb. Reyataz (atazanavir) package insert. Princeton, NJ; 2004.
14. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001;15:991-8.
15. Arribas J, Pulido F, Peng JZ, et al. Evaluation of the multiple-dose pharmacokinetics of lopinavir/ritonavir (LPWR) in HIV and HCV co-infected subjects with mild or moderate hepatic insufficiency. Presented at the 9th European AIDS conference (EACS): 1st EACS resistance and pharmacology workshop, Warsaw, Poland, October 25-29, 2003.
16. Brodie SB, Keller MJ, Ewenstein BM, Sax PE. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS 1998;12:2433-7.
17. Malavaud B, Dinh B, Bonnet E, Izopet J, Payen JL, Marchou B. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther 2000;5:3-5.
18. Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19:825-35.
19. Khaliq T, Gallicano K, Sequin I, et al. Single and multiple dose pharmacokinetics of nelfinavir and CYP 2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol 2000;50:108-15.
20. Regazzi MB, Villani P, Zucchi P, et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in HIV/HCV coinfected patients with and without cirrhosis. Presented at the 4th international workshop on clinical pharmacology of HIV therapy, Cannes, France, March 27-29, 2003.